Mustang Bio Inc (MBIO)

[crudeoil24]

Mustang Bio Inc (NASDAQ: MBIO) announced the publication in the New England Journal of Medicine, of data from a Phase 1/2 trial conducted by St. Jude Children's Research Hospital that is evaluating lentiviral gene therapy for treating newly-diagnosed infants under two years old with XSCID, or SCID-X1, aka bubble boy disease. Mustang Bio has licensed the lentiviral gene therapy for commercial use, and has named it MB-107.

The data showed that the therapy was well tolerated, and seven of the eight treated patients showed normalization of CD3+, CD4+ and CD4+ naïve T-cell and natural killer cell numbers within three to four months after treatment.

"The results have been very good thus far. We've been able to restore a full immune system pretty quickly," the company said.